Akili & Shionogi partnership to bring new digital therapeutics to Asia
Category: #health  By Pankaj Singh  Date: 2019-03-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Akili & Shionogi partnership to bring new digital therapeutics to Asia
  • The new strategic partnership would see the two enterprises collaborate on the development & commercialization of digital therapeutics in crucial Asian markets.
     
  • Potential & upfront milestone payments to Akili for the Taiwan & Japan commercialization are being valued at $125 million.

Akili Interactive (Akili), an American digital medicine company, has reportedly signed a strategic partnership agreement with research-driven Japanese pharmaceutical company, Shionogi & Co., Ltd. (Shionogi) to develop & commercialize digital therapeutics across key markets in Asia.

The collaboration is reportedly to enable the commercialization of Akili’s digital medicines dubbed as AKL-T01 & the AKL-T02, in Taiwan as well as Japan.

According to a press release by Akili Interactive, the AKL-T01 is presently being reviewed by the United States Food & Drug Administration (U.S. FDA), which is determining its credibility as a potential digital therapy for children suffering from attention-deficit/hyperactivity disorder (ADHD). Meanwhile, the AKL-T02 is in the late stages of development and could be used as a potential therapy for cognitive dysfunction & related symptoms for children suffering from Autism Spectrum Disorder (ASD). Both digital treatments are delivered to the patients through immersive action videogames.

The partnership reportedly leverages both enterprise’s unique capabilities to develop a new commercial model & deploy a new class of therapy to the intended patients. Under the terms of the partnership agreement, Shionogi would be responsible for both medicine’s regulatory filings. Moreover, Shionogi would also possess the exclusive rights for the clinical development, marketing & sales of both digital therapeutics across Taiwan & Japan.

Shionogi would reportedly be making an upfront payment totaling $20 million to Akili as part of the deal. Additionally, Akili would also be eligible for substantial commercial & development milestone payments to the tune of $105 million along with significant royalties on both product’s sales in Taiwan & Japan.

According to reports, Akili would be retaining the exclusive global rights for the development & commercialization of both digital therapies across all territories outside of Taiwan & Japan.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
By Pankaj Singh

Japanese automotive giant, Toyota has reportedly tapped Japanese oil & energy corporation, ENEOS, to explore the field of hydrogen-based power to help with the development of a hydrogen fuel-cell system that would power Woven City, Japan’s ...

KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
By Pankaj Singh

Gujarats leading solar power generating company, KPI Global, has recently announced receiving an order for building a 12.5 megawatts solar project under the captive power producer capacity from Surat-headquartered Anupam Rasayan India. It has been r...

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...